Abstract
AIM: Glucose-regulated protein 78 (GRP78) is one of the best-characterized endoplasmic reticulum chaperone proteins. The aim of this study was to explore the potential implications of GRP78 in the development of epithelial ovarian carcinomas (EOCs) and the possible clinical usefulness of GRP78 expression as a prognostic biomarker for EOCs. MATERIALS AND METHODS: A total of 133 women were enrolled. This pilot study consisted of 96 cases of EOCs and 37 cases of benign ovarian tumors as controls. The expression of GRP78 protein was studied using tissue microarray technology and immunohistochemistry. RESULTS: Of the 96 invasive carcinomas analyzed, 25 cases (26.0%) showed moderate GRP78 expression and 65 cases (67.7%) showed strong GRP78 expression. Conversely, 17 (45.9%) of the 37 patients with benign ovarian tumors showed no or weak GRP78 staining. Our results demonstrated that GRP78 expression was significantly higher in EOCs than in benign ovarian tumors (P
Original language | English |
---|---|
Pages (from-to) | 381-385 |
Number of pages | 5 |
Journal | Applied Immunohistochemistry and Molecular Morphology |
Volume | 20 |
Issue number | 4 |
DOIs | |
Publication status | Published - Jul 2012 |
Keywords
- benign ovarian tumor
- epithelial ovarian carcinoma
- GRP78
- immunohistochemistry
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Medical Laboratory Technology
- Histology